Linked Life Data

15034836

Source:http://linkedlifedata.com/resource/pubmed/id/15034836

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15034836rdf:typepubmed:Citationlld:pubmed
pubmed-article:15034836lifeskim:mentionsumls-concept:C0019682lld:lifeskim
pubmed-article:15034836lifeskim:mentionsumls-concept:C0019699lld:lifeskim
pubmed-article:15034836lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:15034836lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:15034836lifeskim:mentionsumls-concept:C0000768lld:lifeskim
pubmed-article:15034836lifeskim:mentionsumls-concept:C0311400lld:lifeskim
pubmed-article:15034836lifeskim:mentionsumls-concept:C0939237lld:lifeskim
pubmed-article:15034836lifeskim:mentionsumls-concept:C1963724lld:lifeskim
pubmed-article:15034836lifeskim:mentionsumls-concept:C1549781lld:lifeskim
pubmed-article:15034836pubmed:issue7lld:pubmed
pubmed-article:15034836pubmed:dateCreated2004-3-22lld:pubmed
pubmed-article:15034836pubmed:abstractTextThe evolution of fasting glucose, triglyceride, and total and high-density lipoprotein (HDL) cholesterol level and the factors associated with development of clinically significant abnormalities in these metabolic parameters at 6 months were assessed in 353 consecutive human immunodeficiency virus (HIV)-infected patients who were receiving antiretroviral therapy containing lopinavir-ritonavir. Although glucose and HDL cholesterol levels did not change, triglyceride and total cholesterol levels significantly increased (P<.0001 for each), as did the proportion of patients with a triglyceride level of >400 mg/dL and a total cholesterol level of >240 mg/dL (P=.002). A baseline triglyceride level of >400 mg/dL and a baseline total cholesterol level of >240 mg/dL were identified as independent factors predicting clinically significant hypertriglyceridemia and hypercholesterolemia, respectively, at 6 months. These findings may have clinical implications when the therapeutic option of lopinavir-ritonavir is considered.lld:pubmed
pubmed-article:15034836pubmed:languageenglld:pubmed
pubmed-article:15034836pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15034836pubmed:citationSubsetIMlld:pubmed
pubmed-article:15034836pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15034836pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15034836pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15034836pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15034836pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15034836pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15034836pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15034836pubmed:statusMEDLINElld:pubmed
pubmed-article:15034836pubmed:monthAprlld:pubmed
pubmed-article:15034836pubmed:issn1537-6591lld:pubmed
pubmed-article:15034836pubmed:authorpubmed-author:DomingoPerePlld:pubmed
pubmed-article:15034836pubmed:authorpubmed-author:MartínezEsteb...lld:pubmed
pubmed-article:15034836pubmed:authorpubmed-author:GatellJosé...lld:pubmed
pubmed-article:15034836pubmed:authorpubmed-author:LarrousseMarí...lld:pubmed
pubmed-article:15034836pubmed:authorpubmed-author:ArroyoJuan...lld:pubmed
pubmed-article:15034836pubmed:authorpubmed-author:de...lld:pubmed
pubmed-article:15034836pubmed:authorpubmed-author:MilinkovicAna...lld:pubmed
pubmed-article:15034836pubmed:authorpubmed-author:GalindoMaría...lld:pubmed
pubmed-article:15034836pubmed:authorpubmed-author:BaldoviFranci...lld:pubmed
pubmed-article:15034836pubmed:authorpubmed-author:LeónAgatheAlld:pubmed
pubmed-article:15034836pubmed:issnTypeElectroniclld:pubmed
pubmed-article:15034836pubmed:day1lld:pubmed
pubmed-article:15034836pubmed:volume38lld:pubmed
pubmed-article:15034836pubmed:ownerNLMlld:pubmed
pubmed-article:15034836pubmed:authorsCompleteYlld:pubmed
pubmed-article:15034836pubmed:pagination1017-23lld:pubmed
pubmed-article:15034836pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:15034836pubmed:meshHeadingpubmed-meshheading:15034836...lld:pubmed
pubmed-article:15034836pubmed:meshHeadingpubmed-meshheading:15034836...lld:pubmed
pubmed-article:15034836pubmed:meshHeadingpubmed-meshheading:15034836...lld:pubmed
pubmed-article:15034836pubmed:meshHeadingpubmed-meshheading:15034836...lld:pubmed
pubmed-article:15034836pubmed:meshHeadingpubmed-meshheading:15034836...lld:pubmed
pubmed-article:15034836pubmed:meshHeadingpubmed-meshheading:15034836...lld:pubmed
pubmed-article:15034836pubmed:meshHeadingpubmed-meshheading:15034836...lld:pubmed
pubmed-article:15034836pubmed:meshHeadingpubmed-meshheading:15034836...lld:pubmed
pubmed-article:15034836pubmed:meshHeadingpubmed-meshheading:15034836...lld:pubmed
pubmed-article:15034836pubmed:meshHeadingpubmed-meshheading:15034836...lld:pubmed
pubmed-article:15034836pubmed:meshHeadingpubmed-meshheading:15034836...lld:pubmed
pubmed-article:15034836pubmed:meshHeadingpubmed-meshheading:15034836...lld:pubmed
pubmed-article:15034836pubmed:meshHeadingpubmed-meshheading:15034836...lld:pubmed
pubmed-article:15034836pubmed:meshHeadingpubmed-meshheading:15034836...lld:pubmed
pubmed-article:15034836pubmed:meshHeadingpubmed-meshheading:15034836...lld:pubmed
pubmed-article:15034836pubmed:meshHeadingpubmed-meshheading:15034836...lld:pubmed
pubmed-article:15034836pubmed:year2004lld:pubmed
pubmed-article:15034836pubmed:articleTitleRisk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.lld:pubmed
pubmed-article:15034836pubmed:affiliationHospital Clínic-Institut d'Investigaciones Biomèdiques August Pi i Sunyer, Valencia, Spain. esteban@fundsoriano.eslld:pubmed
pubmed-article:15034836pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15034836pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15034836lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15034836lld:pubmed